MESO Mesoblast Limited Forecast, Technical & Fundamental Analysis
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions... Show more
MESO is expected to report earnings to fall 100.00% to 0 cents per share on September 02
Q2'26
Est.
$0.00
Q1'26
Est.
$-0.03
Q4'25
Beat
by $0.04
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.36
The last earnings report on June 02 showed earnings per share of -2 cents, meeting the estimate of -2 cents. With 72.02K shares outstanding, the current market capitalization sits at 2.02B.
A.I. Advisor
published General Information
General Information
a company, which engages in the development and commercialization of biological products
A.I.dvisor indicates that over the last year, MESO has been loosely correlated with QTTB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MESO jumps, then QTTB could also see price increases.
MESO in upward trend: 10-day moving average moved above 50-day moving average on August 10, 2026
The 10-day moving average for MESO crossed bullishly above the 50-day moving average on August 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on MESO as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MESO just turned positive on August 10, 2026. Looking at past instances where MESO's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
MESO moved above its 50-day moving average on August 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MESO advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 175 cases where MESO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MESO moved out of overbought territory on July 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MESO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MESO broke above its upper Bollinger Band on July 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MESO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MESO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.521) is normal, around the industry mean (20.443). P/E Ratio (0.000) is within average values for comparable stocks, (24.270). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.844). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (30.488) is also within normal values, averaging (438.852).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
